Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview  by de Freitas, Renata Mendes & da Costa Maranduba, Carlos Magno
rev bras hematol hemoter. 2 0 1 5;3  7(5):348–353
www.rbhh.org
Revista Brasileira de Hematologia e Hemoterapia
Brazilian Journal of Hematology and Hemotherapy
Review article
Myeloproliferative  neoplasms  and  the  JAK/STAT
signaling pathway:  an  overview
Renata Mendes de Freitas ∗, Carlos Magno da Costa Maranduba
Universidade Federal de Juiz de Fora (UFJF), Juiz de Fora, MG, Brazil
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 30 June 2014
Accepted 19 October 2014
Available online 9 June 2015
Keywords:
Hematologic neoplasms
Janus kinase 2
STAT transcription factors
JAK2V617F mutation
a  b  s  t  r  a  c  t
Myeloproliferative neoplasms are caused by a clonal proliferation of a hematopoietic progen-
itor.  First described in 1951 as ‘Myeloproliferative Diseases’ and reevaluated by the World
Health Organization classiﬁcation system in 2011, myeloproliferative neoplasms include
polycythemia vera, essential thrombocythemia and primary myeloﬁbrosis in a subgroup
called breakpoint cluster region-Abelson fusion oncogene-negative neoplasms. According
to  World Health Organization regarding diagnosis criteria for myeloproliferative neoplasms,
the  presence of the JAK2 V617F mutation is considered the most important criterion in
the  diagnosis of breakpoint cluster region-Abelson fusion oncogene-negative neoplasms
and is thus used as a clonal marker. The V617F mutation in the Janus kinase 2 (JAK2) gene
produces an altered protein that constitutively activates the Janus kinase/signal transduc-
ers  and activators of transcription pathway and other pathways downstream as a result of
signal transducers and activators of transcription which are subsequently phosphorylated.
This affects the expression of genes involved in the regulation of apoptosis and regulatory
proteins and modiﬁes the proliferation rate of hematopoietic stem cells.©  2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.Introduction
Myeloproliferative neoplasms (MPNs) are clonal disorders of
hematopoietic stem cells, in which there is an increased
proliferation of the myeloid lineage with effective matura-
tion resulting in peripheral blood leukocytosis, and increased
red blood cell mass; these neoplasms can progress to ﬁbro-
sis or leukemic transformation. The MPNs are a group
of diseases that include polycythemia vera (PV), essential
thrombocythemia (ET) and primary myeloﬁbrosis (PMF),
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reserved.which are collectively known as breakpoint cluster region-
Abelson fusion oncogene (BCR-ABL)-negative neoplasms.
These three diseases share common clinical features, such
as proliferation of hematopoietic stem cells independent of
growth factors, bone marrow hypercellularity, increased risk
of thrombotic events and hemorrhages.1–4
Studies carried out in 2005 identiﬁed abnormalities in the
functioning of the Janus kinase 2 (JAK2) protein which ise Fora, MG, Brazil.
expressed by the JAK2 gene. Here, a sense mutation at exon
14 of the JAK2 gene (g.1849 G>T)5,6 results in the substitu-
tion of a valine for a phenylalanine at position 617 located
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
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n the pseudokinase JH2 domain. It is responsible for consti-
utively activating the JAK/signal transducers and activators
f transcription (STAT) signaling pathway and other pathways
ownstream. The JAK2 V617F mutation occurs at a frequency
f 95% in PV and of 55–60% in ET and PMF.5–10
yeloproliferative  neoplasms
ameshek1 carried out the ﬁrst classiﬁcation of Myelo-
roliferative Diseases in 1951. However, the World Health
rganization (WHO) classiﬁcation system published in 2011
ntroduced a new classiﬁcation of tumors of hematopoietic
nd lymphoid tissue and changed the term to ‘myelopro-
iferative neoplasms’. The MPNs include chronic myeloid
eukemia (CML), PV, PMF,  ET, chronic neutrophilic leukemia
CNL), chronic eosinophilic leukemia (CEL), mast cell dis-
ase (MCD) and unclassiﬁed myeloproliferative neoplasms
MPN-u).11–13 CML  is characterized by the presence of the
hiladelphia chromosome (Ph) resulting from a translocation
etween chromosomes 9 and 22. The resulting hybrid gene,
CR-ABL, encodes a protein of 210 kDa, displaying tyrosine
inase activity and affects growth and cell differentiation.14
In addition to their common features, PV is character-
zed primarily by an increase in red blood cell production, ET
or excessive production of platelets, and PMF  for morpho-
ogical changes in megakaryocytes and the development of
onocytes that lead to the secretion of angiogenic factors
esponsible for promoting ﬁbrosis in the bone marrow.15Table 1 presents the MPN  types, the incidences and clinical
spects of each.
In addition to the JAK2 gene, works carried out since 2005
ave found other mutations in candidate genes, including the
Table 1 – Myeloproliferative neoplasms.
Incidence (cases/100,000 inhabitants/year) 
CML 1.5–1.3 men: 1 woman Leukocyt
PV 0.7–2.6 Headache
pruritus (
and 33% 
myocardi
Bleeding 
PMF 0.5–1.5 25% of pa
such as a
sweats or
tract hem
portal hy
encephal
ET 1–2 A third to
splenome
atypical c
with redn
CNL Rare The incid
Splenom
present. 
CEL 9 men: 1 woman affected About 10
Symptom
and diarr
endomyo
neuropat
may also
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myeloproliferative leukemia (MPL), ten-eleven translocation 2 (TET2)
a member of the TET oncogene family, additional sex comb-like
1 (ASXL1), Casitas B-lineage lymphoma (CBL), isocitrate dehydro-
genase (IDH) and IKAROS family zinc ﬁnger 1 (IKZF1)  genes, all
identiﬁed within the group of BCR-ABL-negative neoplasms.
Mutations in the JAK2 and MPL  encoder genes seem to have
greater effect and are more  associated with PV, ET and PMF
with frequencies around 95%, 55% and 60% for JAK2 and 0%,
0.3% and 10% for MPL.16
The functional consequences of these mutations in MPNs
include disruption of the JAK/STAT signaling pathway, epi-
genetic modulation of transcription as well as abnormal
accumulation of oncoproteins. However, it is still unclear how
all these abnormalities contribute toward disease onset and
clonal evolution of cells.16
Pathogenesis  of  myeloproliferative  neoplasms
In the literature, some evidence suggests that phenotypic
characteristics observed in MPNs are caused due to disor-
ders in the hematopoietic cell signaling process. It has been
reported that hematopoietic progenitors are hypersensitive to
several growth factors in PV, ET and PMF,17 and that abnor-
mal  myeloproliferation in patients with MPNs originates from
constitutive activation of signal transduction pathways. These
are caused by genetic rearrangements or mutations that affect
tyrosine kinases or associated molecules.18 Based on this and
other evidence, some research groups started to work with the
hypothesis that alterations in the function of the JAK2 protein
could be related to MPNs, since this protein is mainly respon-
sible for the activation of molecules involved in cell signaling
processes and red blood cell production.19
Clinical aspects
osis, splenomegaly, weakness, tiredness.
, tiredness, dizziness and sweating. About 40% of patients present
attributed to an increase in histamine and mast cells in the skin),
display thrombotic events (strokes, Budd-Chiari syndrome,
al infarction, pulmonary embolism or deep venous thrombosis).
has also been documented in 25% of cases.
tients are asymptomatic. The rest present secondary symptoms
nemia, splenomegaly, hypermetabolic state (weight loss, night
 fever), extramedullary erythropoiesis, bleeding (gastrointestinal
orrhage), osseous abnormalities (joint pain or osteosclerosis), and
pertension (ascites, gastric or esophageal varices, hepatic
opathy, portal or hepatic vein thrombosis).
 a quarter of patients are symptomatic and 25–48% show
galy. Vasomotor symptoms, characterized by headache, syncope,
hest pain, and erythromelalgia (burning of hands or feet associated
ess and heat) are observed in about 40% of cases.
ence as well as the etiology is unknown. It affects the elderly.
egaly, hepatomegaly and mucosal or gastrointestinal bleeding are
It is a disease with a slowly progressive clinical course.
% of patients are diagnosed by chance since they are asymptomatic.
s such as fever, fatigue, cough, angioedema, muscle pain, pruritus
hea are common. Anemia, thrombocytopenia, mucosal ulceration,
cardial ﬁbrosis and splenomegaly are also common. Peripheral
hy, central nervous system dysfunction and pulmonary symptoms
 be present.
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The  Janus  kinase  2  gene
The JAK2 gene, located on chromosome 9p24 in humans,
includes 25 exons encoding a protein of about 1132 amino
acids. This protein is named JAK2 and it is a member of the
Janus kinase (JAK) family. Four members of this family have
already been identiﬁed: JAK1, JAK2, JAK3 and Tyk2.20
In 2005, the discovery of the JAK2 mutation (JAK2 V617F)
expanded the knowledge about the pathogenesis of BCR-ABL-
negative neoplasms. A missense mutation at position g.1849
with a guanine-thymine transversion (g.1849 G>T)5,6 was iden-
tiﬁed in exon 14 of the JAK2 gene. This mutation results in the
substitution of valine for phenylalanine at amino acid position
p.617,5 affecting the pseudokinase domain (JH2) of the protein.
The JAK2 V617F mutation is present in most patients with PV
and in a subgroup of patients with ET and PMF  (∼95% in PV,
50–60% in ET and 50–60% in PMF).5–9,19
It has been shown that the JAK2 V617F mutation
causes genetic instability in gene expression by induc-
ing changes in the chromatin structure and by reducing
the apoptotic response to DNA damage. These are mech-
anisms that can increase the accumulation of genetic
lesions leading to malignant transformations.12 Besides the
g.1849 G > T (p.V617F) mutation,5,6 other mutations were
found in exon 12 in 2007 namely: p.N542-543del, p.E543-
D544del, p.K539L, p.F537-K539delinsL, p.H538-p.K539delinsL,
p.H538QK539L, p.V536-1546dup11, p.F537-1546dup10+F547L,
p.R541 E543delinsK-and-p.I540 E543delinsMK.21–23 These were
found to show low frequencies of about 3–4% in PV patients.
There are valid techniques that detect these mutations and
their active search is justiﬁed not only due to the absence of
the exon 14 mutation, but also in patients that have erythro-
cytosis and in those with low levels of erythropoietin.24
The  Janus  kinase  2  protein
Members of the JAK2 protein family have seven homologous
domains (JH) that are numbered from 1 to 7. The JH1 domain
acts as a kinase domain, which contains the adenosine
triphosphate (ATP)-binding and signaling pathway activation
regions. The JH2 domain is a pseudokinase that is homologous
to the JH1 domain. It lacks catalytic activity due to a substitu-
tion of an aspartate residue in the catalytic loop (His–Arg–Asp –
HRD motif). JH2 has an inhibitory function that regulates both
the basal activity of JAK and the cytokine-induced activation
by interacting with the active site, JH1, blocking ATP and/or
substrates binding to the catalytic site.25–27
Mutations in exon 12 of JAK2 are found in the binding
region of the Src homology 2 (SH2) and JH2 domains. Although
not directly located in the JH2 domain, these mutations may
modify the structure of the pseudokinase domain, inducing
erythropoietin hypersensitivity similar to that caused by the
JAK2 p.V617F mutation.5,9,28,29
The  Janus  kinase  2/signal  transducers  and  activators  of
transcription  signaling  pathwaySignaling  receptors
Cytokines from the hematopoietic system include inter-
leukins (ILs), colony stimulating factors (CSFs), interferon 2 0 1 5;3  7(5):348–353
(INF), erythropoietin (EPO) and thrombopoietin (TPO) all of
which activate the signal transduction of the JAK/STAT
signaling pathway.30,31 Most of these receptors are part of a
type I-homodimer receptor family, that includes the erythro-
poietin (EPO-R) and thrombopoietin (TPO-R) receptors.32
The type I receptor is speciﬁcally expressed during ery-
throid and myeloid differentiation and its expression may
account for the preferential activity of JAK2 V617F over
myeloid lineage cells rather than lymphoid lineage cells,
which lack this type of receptor.32
Janus  kinases
JAKs are associated with the intracellular domains of cytokine
receptors; they show intrinsic kinase activity mediated
through their band-4.1 protein, ezrin, radixin, and moesin
(FERM) and SH2 domains and are kept in an inactive state in
the absence of speciﬁc receptor-activating ligands.33,34
Cytokine binding leads to a conformational change of
the receptor, cytoplasmically affecting associated JAKs, caus-
ing activation and phosphorylation. Phosphorylated tyrosine
residues in JAKs act as binding sites for the SH2 domains
in signaling molecules. Mutations in JAK2 generate con-
stitutive activation of the JAK/STAT pathway, mainly in
STAT3 and STAT5. In addition to ‘hot spot’ mutations,
constitutive activation of tyrosine kinases also occurs by
chromosomal translocation, deletion and tandem duplica-
tion, which are common pathogenic events in hematopoietic
malignancies.10,27,31–35
The STATs are located in the cytosol and migrate to the
nucleus, regulating gene transcription only upon activation.
Once associated with the phosphorylated sites of JAK, these
STATs also phosphorylate and dimerize.26
Dimerized STATs migrate toward the nucleus, where they
act as transcription factors, activating or repressing genes
that are important in cell proliferation and survival. Some of
these genes include those that express cyclins as well as anti-
apoptotic proteins.36 STAT dimers also activate genes that
encode inhibitory proteins that contribute toward the termi-
nation of cellular response. Some of these proteins bind to
phosphorylated JAKs and inactivate them, as well as their
associated receptors. Others bind to phosphorylated STAT
dimers and stop them from binding to their target gene.37
JAK/STAT-mediated signaling control mechanisms include
dephosphorylation of JAK and STAT. This is caused by an inhi-
bition triggered by suppressors of cytokine signaling (SOCS)
proteins, the lymphocyte adaptor protein (LNK also known as
SH2B3) and CBL.30,32
Negative  regulation  of  the  Janus  kinase  2/signal
transducers  and  activators  of  transcription  pathway
As our knowledge about the JAK/STAT pathway has increased,
important mechanisms for down-regulation of this pathway
have been elucidated. These include removal of phosphates
from cytokine receptors and activated STATs by tyrosine phos-
phatases, as well as by protein inhibitors of activated STAT
(PIAS). PIAS inhibit transcriptional activation by binding and
blocking access to target DNA. The next section will discuss
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hree PIAS: SOCS, CBL and Lyme neuroborreliosis (LNB) pro-
eins.
SOCS proteins are a family of cytokine signaling suppres-
ors of the JAK/STAT pathway, characterized by the presence of
n amino-terminal domain that is variable in size. It includes
n inhibitory domain, a SH2 domain and a carboxy-terminal
omain called SOCS box. Currently, there are eight mem-
ers in this family, namely: SOCS1, SOCS2, SOCS3, SOCS4,
OCS5, SOCS6, SOCS7 and CIS. Under normal conditions, they
re expressed at low levels in unstimulated cells while their
xpression increases when STATs are activated.30,31,38
SOCS can inhibit the JAK/STAT signaling through two
echanisms: (1) inhibition of JAK2 kinase activity by com-
eting with the STATs SH2 domains for binding sites in the
ytoplasmic domain of the receptor or (2) proteasomal degra-
ation of signaling proteins by binding to the JH1 domain of
AK2, inhibiting the activation of all other JAK/STAT-associated
athways.39
Some mutations in different SOCS have been identiﬁed in
PNs, but are rarely found. Hypermethylation of CpG islands
n SOCS1 and SOCS3 is associated with a decrease in the
xpression of these regulators in p.V617F-positive PV and ET
atients.5,10
Other important components of this negative regula-
ory complex include multifunctional proteins with ubiquitin
igase activity, such as CBL. CBL is usually involved in the
egative feedback of tyrosine kinase receptors by competi-
ive blocking signaling. It induces proteasomal degradation of
yrosine kinases activated by ubiquitination. All CBL have sin-
le domain proteins that recognizes phosphorylated tyrosine
esidues that are present on activated tyrosine kinases.10,40
EPO-R
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igure 1 – Signaling pathways activated by cytokine receptor bin
hosphorylation of JAK2. The active negative feedback regulatory
neffective in the presence of a mutation in the JH2 domain of JA
TAT: signal transducers and activators of transcription; JAK2: Ja
uppressors of cytokine signaling; Bcl-XL: B-cell lymphoma-extr 1 5;3  7(5):348–353 351
LNK, included in the SH2B protein family, negatively reg-
ulates the activity of JAK2 by binding to SH2-phosphorylated
tyrosine. It also regulates the signaling of TPO-R and EPO-R,
and it is detected in both JAK2 V617F-positive and -negative
patients.10 Increased LNK deﬁciency increases the oncogenic
ability of JAK2 to expand myeloid progenitors in vitro and
in vivo.41
Mutation  in  the  Janus  kinase  2  gene  and  changes  in
protein  function
In addition to activating the JAK/STAT pathway, the p.V617F
mutation5 also constitutively activates the rat sarcoma
(RAS)/Mitogen-activated protein kinases (MAPK) and phos-
phoinositide 3-kinase (PI3K)/protein kinase B (PKB, aka Akt)
pathways, which results in an increased expression of mitotic
proteins, regulatory proteins from the cellular cycle [cyclins
D1, CDC25A (cell division cycle)] and anti-apoptotic genes
[B-cell lymphoma-extra-large (Bcl-XL) and Bcl2]. These abnor-
malities involving the JAK/STAT and related pathways result
in proliferation of affected cells (Figure 1).10
In mutated cells, down-regulation becomes inadequate
and/or inefﬁcient. SH2 domains, normally present in PIAS
proteins, cannot dephosphorylate JAK2. In addition, the anti-
apoptotic mechanisms are expressed at much higher levels
than normal. An acquired mutation in one of these regulatoryAdditional molecular events appear to interfere with
the activity of JAK2, such as cytogenetics, which increase
STAT
socs
JAK2JAK2JAK2
P P
P P
P P
P P
P
STAT3,
STAT5
Negative
feedback
SOCS, Bcl-xl, p21, MYC etcoter
ding. PI3K, Akt and STAT are activated after the
 proteins complete the activation pathways. Such control is
K2. PI3K: phosphoinositide 3-kinase; Akt: protein kinase B;
nus kinase 2; EPO-R: erythropoietin receptor; SOCS:
a-large; Myc: myelocytomatosis oncogene.
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the kinase activity of the protein, the regulatory ability
of phosphorylases and SOCS proteins, polymorphisms, and
mutations in cytokine receptors.43
Questions  about  the  different  phenotypes  in
BCR-ABL-negative  myeloproliferative  neoplasms  and  the
V617F  mutation
A further intriguing question for researchers regarding MPNs
is how the same mutation can trigger three phenotypically
different diseases. There is still no clear understanding of the
molecular mechanisms involved in the process, just hypothe-
ses. One of them is the dose–response gene hypothesis, which
is associated with allele load. Another is that there may be
epigenetic changes that predispose the patient’s organism to
develop certain MPNs as well as changes in genes speciﬁc
in the development of malignancies, as well as mutations in
other signaling pathways that might affect signaling in regu-
latory proteins.16
For Kralovics et al., Plo et al., Smith & Fan, Cross and
Pagliarini,26,44–47 the phenotype of the disease is related to the
concept of allelic load. Thus, low levels of mutant alleles would
result in ET phenotype, while higher levels of mutated alleles
would lead to a phenotype similar to PV. These higher levels of
mutated alleles in hematopoietic stem cells could be associ-
ated with the patient’s homozygous condition, caused by loss
of heterozygosity, as explained by the theory of uniparental
disomy.48
Presumably, homozygosity confers a proliferative advan-
tage over other cells, which present only one mutated allele,
increasing the activity level of the tyrosine kinase generated
by the mutated JAK2. Patients with ET and PMF are mostly
heterozygous and seldom show homozygosity.48
Besides the association between phenotype and homozy-
gosity/heterozygosity, there are other hypotheses that have
attempted to correlate the different phenotypes observed
related to the JAK2 V617F mutation.
In their study, Plo et al.45 discuss the gene-dose hypothe-
sis, which postulates that the JAK2 mutation can be a starting
point for the three pathologies. They also discuss the exist-
ence of other genetic events that can modify the JAK2 kinase
activity, which may explain the heterogeneity present in clas-
sic MPNs. Several mechanisms have been proposed to aid the
understanding of loss of heterozygosity and/or the presence
of new genetic abnormalities, including the double-stranded
break repair mechanisms in DNA, homologous recombination
and non-homologous end joining. All these lead to genomic
instability, which highlights how essential the precise regula-
tion of these mechanisms is for the maintenance of genome
stability and diversity.49–51
According to Mascarenhas et al.52 biological events that
lead to the initiation and progression of MPNs are linked not
only to acquisition of genetic mutations such as JAK2 V617F.
They are also due to epigenetic changes that do not affect the
primary DNA sequence, but the gene expression responsible
for chromatin remodeling. Deregulation of modulation pro-
cesses between nucleosomes may result in silencing of tumor
suppressor as well as differentiation genes, promoting cell sur-
vival by blocking apoptosis and senescence, contributing to
malignant transformation. The researchers also highlighted
1 2 0 1 5;3  7(5):348–353
two categories of epigenetic alterations in MPNs: (1) changes
in the genes that encode proteins involved in remodeling of
the chromatin structure, such as the TET2, ASXL1,  JAK2 genes,
among others, and (2) changes in the promoter site of genes
essential for cell survival, differentiation and proliferation.
Besides its role in signaling, the JAK2 V617F mutation also
affects chromatin structure by blocking the recruitment of
repressor proteins.9
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